UNSPSC 51432007: Sitaxentan sodium

This classification denotes an endothelin-1 protein receptor antagonist C18H14ClN2O6S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6V9JH46E20, chemically known as n-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-(2-(6-methyl-2h-1,3-benzodioxol-5-yl)acetyl)thiophene-3-sulfonamide sodium salt, but more generally known as sitaxentan sodium, which bears US NIH Compound Identifier 11477084. European Medicines Agency schedules Sitaxentan sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22351.

Most nations, for tariff and trade purposes, schedule sitaxentan sodium under HS 29350090 and SITC 51580. As of Q4 2014, SITAXENTAN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C(CC1CC(=O)C3C(CCS3)S(=O)(=O)[N-]C4C(C(NO4)C)CL)OCO2.[NA+].

UNSPSC 51432007 Sitaxentan sodium is a Commodity code that covers pharmaceutical active pharmaceutical ingredients and branded or generic drugs. State and local governments procure medications under this code primarily for emergency medical services, public health programs, and multistate cooperative purchasing agreements that supply medications to government health facilities and employee health plans. The City of Tampa's Fire Rescue department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of issuing bodies—municipal emergency services, state health agencies, and cooperative purchasing organizations that aggregate demand across multiple jurisdictions. Recent solicitations show demand for advanced life support medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription fulfillment programs that bypass traditional pharmacy benefit manager intermediaries.

Activity under this code concentrates in Florida, Texas, and Minnesota, with the Minnesota cooperative extending into Oregon. The City of Tampa issued Solicitation 26P00188 (IFB, due April 8, 2026) for advanced life support medications with an estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, with contract terms of two years for new vendors and alignment with existing agreements through June 30, 2028 for incumbents; award is weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 (closed April 3, 2026) to gather vendor capabilities regarding direct-to-manufacturer prescription programs for self-insured state employee health plans, an early-stage market intelligence activity preceding formal solicitation.